Antibiotics

The company is advancing R327G, a novel synthetic anti-infective for diabetic foot infections, through a phase 3 clinical trial in Indonesia, marking a major step toward the first new anti-infective class approval in over 40 years.

Despite modest progress, Staphylococcus aureus bloodstream infections—particularly those caused by MRSA—remain a major cause of morbidity and mortality, underscoring the urgent need for novel, broad-spectrum treatments such as ceftobiprole that can address both resistant and susceptible strains.

University of Oregon researchers found that adding a common chemical, chlorate, to standard antibiotics made them up to 10,000 times more effective in lab tests against hard-to-treat bacteria, offering a potential breakthrough for chronic wound care.

Infections caused by NDM-producing carbapenem-resistant Enterobacterales have risen more than 4-fold since 2019, raising alarms about limited treatment options, delayed detection, and heightened risks of transmission and mortality in health care settings. TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on NDM-CRE, antimicrobial resistance, and an overview of his company’s pipeline.

Recce Pharmaceuticals has begun its study for this indication in Indonesia with its investigational product, RECCE 327 topical gel (R327G).

Stewardship programs that reduce initial use of extended-spectrum antibiotics appear to influence antibiotic choice throughout hospitalization.

William Schaffner, MD, reviews clinical workup, treatment, and preventative measurements.

The 2025 ATS guidelines for community-acquired pneumonia update recommendations on imaging, antibiotic use, treatment duration, and corticosteroid use, emphasizing lung ultrasound as an alternative diagnostic tool, more selective empiric antibiotic prescribing, shorter courses of antibiotics for stable patients, and limited use of corticosteroids to severe inpatient cases.

Jennifer Le, PharmD, MAS, FIDSA, FCCP, FCSHP, discusses her collaboration on this innovative work with this therapy in severely ill children.

A CDC report links the rapid growth of NDM-CRE to testing gaps and urges the prompt use of carbapenemase testing, mechanism-guided therapy, and stronger infection prevention measures.

This week, OPAT for gram-negative infections expands to outpatients amid infusion complexity and stability limits, HHS and CDC add five ACIP members days before meeting, and more.

Bordetella bronchiseptica is a rare human respiratory pathogen that can be initially confused for Bordetella pertussis, leading to potentially inadequate treatment. This article reviews the organism and recent literature on the successful treatment of B bronchiseptica.

In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.

Compared to culture/sensitivity results (C/S) results, ICU-based PCR testing of hospital-acquired pneumonia was associated with lower treatment costs and better antibiotic stewardship, but not higher cure rates.

Iterum Therapeutics has launched its sulopenem etzadroxil and probenecid (Orlynvah), which is the first and only oral penem antibiotic in the US.

Ciprofloxacin monotherapy was non-inferior to aminoglycoside/ciprofloxacin combination for bubonic plague in multi-year trial in endemic region.

The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.

Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen that poses significant treatment challenges due to its complex resistance mechanisms, limited therapeutic options, and high mortality rates among vulnerable patients.

Clinical trial and real-world data, including the PROVE study, support its role as an effective and carbapenem-sparing therapy for serious infections, though outcomes vary depending on pathogen and infection type.

Doxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.

A recent literature review describes the current state of artificial intelligence tools for guiding antimicrobial therapy. Are you ready for change?

If this GSK antibiotic is approved, it will provide a new oral option to patients in the US who are currently relying on injectable treatments.

A multi-prong approach reduces inappropriate antibiotic prescribing to outpatients with upper respiratory tract infection.

Athena Hobbs, PharmD, BCIDP, looked at this issue through the lens of treating urinary tract infections.

Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.